Reversal of cisplatin resistance in vivo by an anti-fos ribozyme

Tadao Funato, Tomonori Ishii, Mariko Kanbe, Kevin J. Scanlon, Takeshi Sasaki

研究成果: Article査読

20 被引用数 (Scopus)

抄録

Human colon cancer cells, SW480DDP and SW620DDP, which express fos gene highly, are resistant to cisplatin treatment. We prepared a hammerhead ribozyme to selectively cleave fos mRNA and revealed that the fos ribozyme significantly suppressed the expression of fos gene in resistant cells in vitro. The fos ribozyme which was transfected into the implanted tumor cells resistant to cisplatin, had also the ability to reduce the expression of fos gene in vivo, and reversed cell sensitivity to cisplatin. These results reinforce the potential role of anti-oncogene ribozymes in dealing with the problem of drug resistance, with new possible implications for gene targetting therapy.

本文言語English
ページ(範囲)217-220
ページ数4
ジャーナルIn Vivo
11
3
出版ステータスPublished - 1997 5

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

フィンガープリント 「Reversal of cisplatin resistance in vivo by an anti-fos ribozyme」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル